title: Combination of low concentration of (-)-epigallocatechin gallate (EGCG) and curcumin strongly suppresses the growth of non-small cell lung cancer in vitro and in vivo through causing cell cycle arrest.
abstract: (-)-Epigallocatechin gallate (EGCG) and curcumin are two naturally derived agents that have been widely investigated worldwide. They exhibit their anti-tumor effects in many types of cancers. In the current study, the effect of the combination of the two agents on non-small cell lung cancer (NSCLC) cells was investigated. The results revealed that at low concentrations, the combination of the EGCG and curcumin strongly enhanced cell cycle arrest. Flow cytometry analysis showed that the cells were arrested at G1 and S/G2 phases. Two main cell cycle related proteins cyclin D1 and cyclin B1 were significantly inhibited at the present of EGCG and curcumin. EdU (5-ethynyl-2'-deoxyuridine) fluorescence staining showed that the DNA replication was significantly blocked. A clonal growth assay also confirmed a marked repression of cell growth. In a lung cancer xenograft node mice model, combination of EGCG and curcumin exhibited protective effect against weight loss due to tumor burden. Tumor growth was strongly repressed by the combination of the two agents, without causing any serious side-effect. Overall, these results strongly suggest that EGCG in combination with curcumin could be a candidate for chemoprevention agent of NSCLC.
authors.affiliation: Department of Nutrition and Food Safety, Nanjing Medical University, Nanjing 211166, Jiangsu, China. qingfeng@njmu.edu.cn.
authors.forename: Dong-Hu
authors.initials: DH
authors.lastname: Zhou
authors.forename: Xuemin
authors.initials: X
authors.lastname: Wang
authors.forename: Mingmin
authors.initials: M
authors.lastname: Yang
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Shi
authors.forename: Wenbin
authors.initials: W
authors.lastname: Huang
authors.forename: Qing
authors.initials: Q
authors.lastname: Feng
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology*; D002392:Catechin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002999:Clone Cells; D003474:Curcumin / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D056744:Cyclin B1 / Q000378:metabolism; D019938:Cyclin D1 / Q000378:metabolism; D004261:DNA Replication / Q000187:drug effects; D005260:Female; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008807:Mice, Inbred BALB C; D008819:Mice, Nude
chemical_list: D016588:Anticarcinogenic Agents; D056744:Cyclin B1; D019938:Cyclin D1; D002392:Catechin; C045651:epigallocatechin gallate; D003474:Curcumin